Familial Hypercholesterolemia
In people ordering genetic CV tests, positive result rate varies with age
Among people who ordered a genetic test for dyslipidemia, younger people were more likely to have a positive result than older people, according to a presentation at the National Lipid Association Scientific Sessions.
Evolocumab gains FDA approval for patients aged 10 years and older with heterozygous FH
Amgen announced that the FDA has approved evolocumab as an adjunct to diet and other LDL-lowering therapies for the treatment of heterozygous familial hypercholesterolemia in pediatric patients aged 10 years and older.
Educational outreach via direct messaging may improve FH screening, diagnosis
Messaging built into an existing electronic health records system to directly connect physicians may increase screening and diagnosis of familial hypercholesterolemia among patients identified as being high risk, a speaker reported.
Future therapeutics may dramatically lower LDL
LDL-lowering therapeutics have evolved since the introduction of bile acid sequestrants in 1973, and approaches in development may prove even more effective than those in the past and present, according to a speaker.
NLA issues new recommendations on lipid measurements in the management of CVD
Accurate and precise laboratory lipid measurements are important. As such, the National Lipid Association has released a new scientific statement on lipid measurements in the management of CVDs.
FDA requests removal of strongest warning against statin use among pregnant women
The FDA requested removal of its contraindication against using cholesterol-lowering statin medicines among pregnant patients; however, most patients should stop statins once they learn they are pregnant.
COVID-19 may increase risk for MI in patients with ASCVD, familial hypercholesterolemia
Adults with preexisting atherosclerotic CVD and/or familial hypercholesterolemia have increased risk for acute MI if infected with COVID-19, according to an analysis published in the American Journal of Preventive Cardiology.
FDA approves expanded indication for alirocumab as add-on therapy for homozygous FH
The FDA has approved the expanded indication for alirocumab injection for adult patients with homozygous familial hypercholesterolemia, or HoFH, as an add-on therapy to other treatments for HoFH.
Rosuvastatin/ezetimibe tablet approved for LDL reduction in hyperlipidemia, HoFH
Althera announced the FDA approved its rosuvastatin/ezetimibe tablets as an adjunct to diet for treatment of elevated LDL in adults with primary nonfamilial hyperlipidemia or homozygous familial hypercholesterolemia.
FDA approves evinacumab for homozygous FH
Regeneron announced the FDA has approved evinacumab for treatment of patients aged 12 years or older with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies.